Cryolife Inc (CRY) VP David Ashley Lee Sells 25,255 Shares

Cryolife Inc (NYSE:CRY) VP David Ashley Lee sold 25,255 shares of the firm’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $31.36, for a total transaction of $791,996.80. Following the sale, the vice president now owns 300,910 shares in the company, valued at $9,436,537.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of CRY stock traded up $0.21 during trading hours on Friday, reaching $28.75. 280,442 shares of the stock were exchanged, compared to its average volume of 197,456. Cryolife Inc has a 12-month low of $23.99 and a 12-month high of $36.05. The company has a current ratio of 4.90, a quick ratio of 3.69 and a debt-to-equity ratio of 0.86. The stock has a market cap of $1.05 billion, a PE ratio of 110.58 and a beta of 0.54.

Cryolife (NYSE:CRY) last released its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.04 EPS for the quarter, hitting analysts’ consensus estimates of $0.04. The firm had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $66.37 million. Cryolife had a negative net margin of 0.09% and a positive return on equity of 3.79%. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.02 EPS. Sell-side analysts forecast that Cryolife Inc will post 0.31 EPS for the current year.

Several brokerages have recently commented on CRY. Needham & Company LLC restated a “hold” rating on shares of Cryolife in a research report on Wednesday, May 1st. TheStreet upgraded shares of Cryolife from a “c” rating to a “b-” rating in a report on Wednesday, May 1st. Canaccord Genuity reiterated a “buy” rating and issued a $35.00 price target (up from $32.00) on shares of Cryolife in a report on Wednesday, May 1st. ValuEngine downgraded shares of Cryolife from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 15th. Finally, Zacks Investment Research cut shares of Cryolife from a “hold” rating to a “sell” rating in a research note on Wednesday, February 20th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $31.91.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in shares of Cryolife by 2.8% in the 4th quarter. BlackRock Inc. now owns 5,533,113 shares of the medical equipment provider’s stock valued at $157,030,000 after purchasing an additional 152,026 shares in the last quarter. Vanguard Group Inc raised its holdings in shares of Cryolife by 2.7% in the 3rd quarter. Vanguard Group Inc now owns 2,017,304 shares of the medical equipment provider’s stock valued at $71,009,000 after purchasing an additional 53,676 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Cryolife by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,017,304 shares of the medical equipment provider’s stock valued at $71,009,000 after purchasing an additional 53,676 shares in the last quarter. Macquarie Group Ltd. raised its holdings in shares of Cryolife by 0.3% in the 4th quarter. Macquarie Group Ltd. now owns 1,635,234 shares of the medical equipment provider’s stock valued at $46,408,000 after purchasing an additional 5,474 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its holdings in shares of Cryolife by 8.8% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 553,254 shares of the medical equipment provider’s stock valued at $16,138,000 after purchasing an additional 44,748 shares in the last quarter. 71.44% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Cryolife Inc (CRY) VP David Ashley Lee Sells 25,255 Shares” was first posted by Rockland Register and is the property of of Rockland Register. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://rocklandregister.com/2019/05/31/david-ashley-lee-sells-25255-shares-of-cryolife-inc-cry-stock.html.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Featured Article: What is a Real Estate Investment Trust (REIT)?

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.